Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Jindřich Špinar et al.|New England Journal of Medicine|2021Cited by 4.6k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Christiane E. Angermann et al.|Nature Medicine|2022Cited by 889
Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by DoxorubicinTomas G. Neilan, Kenneth D. Bloch, Sarah L. Blake et al.|Circulation|2007Cited by 167
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialMilton Packer, Faı̈ez Zannad, Stefan D. Anker et al.|European Heart Journal|2020Cited by 135
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialStefan D. Anker, Milton Packer, Javed Butler et al.|European Journal of Heart Failure|2020Cited by 135